Syndax Pharmaceuticals Financial Statements
NASDAQ: SNDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Syndax Pharmaceuticals revenue and earnings
In fiscal 2025, Syndax Pharmaceuticals generated $172.4 million in revenue, up 627.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Syndax Pharmaceuticals reported a net loss of $285.4 million, compared with a loss of $318.8 million a year earlier. Operating margin was -158.4%.
Diluted earnings per share came in at -$3.29. Over the last 5 fiscal years, SNDX's revenue has grown at a 157.7% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Syndax Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 172.35M | 23.68M | 0 | 0 | 139.71M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M |
| Revenue growth (YoY) | +627.84% | — | — | -100.00% | +9109.56% | 0.00% | 0.00% | -28.04% | +72.79% | +94.58% |
| Operating Expenses | 445.44M | 363.35M | 229.95M | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M | 64.06M | 44.99M |
| Research & Development | 258.78M | 241.65M | 163.03M | 118.50M | 88.25M | 50.44M | 42.99M | 60.11M | 48.20M | 31.66M |
| Selling, General & Admin | 179.68M | 120.88M | 66.92M | 33.26M | 25.24M | — | — | — | — | — |
| Operating Income | -273.08M | -339.67M | -229.95M | -151.76M | 26.22M | -71.42M | -57.54M | -75.88M | -61.95M | -43.77M |
| Interest Expense | 6.00K | -1.00K | 208.00K | 3.14M | 1.90M | 2.36M | — | — | — | — |
| Other Income (Expense) | -12.34M | 20.91M | 20.59M | 2.42M | -1.29M | -1.74M | 1.49M | 1.92M | 1.15M | -706.00K |
| Income Tax | 433.00K | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -285.42M | -318.76M | -209.36M | -149.34M | 24.93M | -73.16M | -56.05M | -73.96M | -60.80M | -44.47M |
| Net Income growth (YoY) | — | — | — | -699.13% | — | — | — | — | — | — |
| EPS (Basic) | -3.29 | -3.72 | -2.98 | -2.46 | 0.48 | -1.87 | -1.84 | -2.92 | -2.90 | -3.22 |
| EPS (Diluted) | -3.29 | -3.72 | -2.98 | -2.46 | 0.46 | -1.87 | -1.84 | -2.92 | -2.90 | -3.22 |
| Shares Outstanding (Basic) | 86.63M | 85.62M | 70.37M | 60.76M | 52.06M | 41.31M | 30.49M | 25.37M | 21.00M | 14.62M |
| Shares Outstanding (Diluted) | 86.63M | 85.62M | 70.37M | 60.76M | 53.62M | 41.31M | 30.49M | 25.37M | 21.00M | 14.62M |
| EBITDA | -267.08M | -331.67M | -217.95M | -118.76M | 69.22M | -71.33M | -57.45M | -75.80M | -61.88M | -43.68M |
| Operating Margin | -158.45% | -1434.43% | — | — | 18.77% | -4708.17% | -3792.95% | -5001.71% | -2938.99% | -3587.38% |
| Net Margin | -165.60% | -1346.11% | — | — | 17.84% | -4822.54% | -3694.59% | -4875.48% | -2884.35% | -3645.25% |
This table shows 10 annual periods of Syndax Pharmaceuticals's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow SNDX's reporting calendar. What is a income statement?